Trials / Completed
CompletedNCT01279954
Abatacept in the Treatment of Uveitis
An Openlabel, Phase II Trial of Abatacept (Orencia) in the Treatment of Refractory Non-infectious Uveitis.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Oregon Health and Science University · Academic / Other
- Sex
- All
- Age
- 6 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and efficacy of abatacept in the treatment of uveitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Abatacept | Subjects will receive approximately 10 mg/kg rounded to the nearest 25 mg for the first 6 months of the trial. At 6 months subjects will then be randomized to receive either 5 mg/kg or 10 mg/kg. Abatacept will be administered as a 30-minute intravenous infusion. Following the initial administration, abatacept will be given at 2 and 4 weeks after the first infusion and every 4 weeks thereafter for up to 2 years. |
Timeline
- Start date
- 2012-01-01
- Primary completion
- 2017-06-01
- Completion
- 2017-06-01
- First posted
- 2011-01-20
- Last updated
- 2019-02-21
- Results posted
- 2019-02-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01279954. Inclusion in this directory is not an endorsement.